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A recent “hot topic” in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence
of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery
may inﬂuence plasma level of inﬂammatory molecules and this might result in enhanced radiosensitivity. We here present
results on the feasibility of monitoring the expression of inﬂammatory molecules during radiotherapy. Plasma levels of a panel
of soluble mediators associated with the inﬂammatory response were measured in prostate cancer patients undergoing radical
radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long
pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78Gy. 3/20
patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting
marker showing signiﬁcant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using
linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity
had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.
1. Introduction
Prostate cancer is one of the most common tumours in the
Western world. Radical prostatectomy and radiotherapy
represent the two standard treatments. Both can be aﬀected
by signiﬁcant side eﬀects that can adversely condition
patients’ quality of life.
In the past decade, many advances have been made in
terms of treatment outcomes and reduction of the side eﬀects
experienced by prostate cancer survivors. In the ﬁeld of
radiotherapy, this was primarily achieved through the intro-
duction of sophisticated radiotherapy technologies. They
allow the delivery of highly conformal doses to the tumor
target through intensity modulated beams (IMRT), volumet-
ric arcs ((volumetric modulated arc therapy (VMAT)), and
precise image guidance (IGRT).
Nevertheless, a portion of the patient still suﬀers from
radiation-induced toxicity and the availability of tools
predicting unusual radiation toxicity could be crucial in
improving the potential of individualizing the treatment with
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respect to several aspects, concerning the choice of the
therapeutic strategy, dose prescription, fractionation, and
use of supportive therapies.
A recent “hot topic” in prostate cancer radiotherapy is
the observed association between acute/late rectal toxicity
and the presence of abdominal surgery before radiotherapy
[1, 2]. The reasons why surgery procedures not directly
involving the irradiated volume may be so strongly corre-
lated to late intestinal toxicity are still unknown and only
some hypothesis can be suggested. It has been speculated
that previous surgery may act throughout a limitation in
blood supply and/or in reducing bowel movements [2].
The working hypothesis, which guided the present study,
was that a previous surgery may inﬂuence plasma level of
inﬂammatory molecules/cytokines, and this fact might result
in an enhanced radiosensitivity. Surgery could function as a
potential precursor of inﬂammatory patterns that could lead
to an increased sensitivity even far from the surgical injury
through cytokine-mediated reactions.
Cytokines are small proteins released by cells that act via
receptors. The important role that cytokines play inmediating
radiation toxicity was ﬁrst reported by Rubin [3]; later,
Okunieﬀ [4] elucidated the link between inﬂammation, ﬁbro-
sis, and tissue restitution. Some other investigators have even
shown that the levels of inﬂammatory cytokines in individual
animals of the same strain aﬀects the severity of toxicity
from animal to animal [5]. It is also well established that
patients with intrinsically high inﬂammatory states (e.g.,
collagen vascular disease and autoimmune disease) are at
extremely high risk of severe ﬁbrosis after pelvis radiotherapy
[6] and thus, we could expect that the variability of these
cytokines among patients might explain the wide variability
of clinical toxicity.
The role of these inﬂammatory molecules in the response
of tissues to irradiation has also been related to the abscopal
eﬀect through adaptive immune responses [7].
The present analysis [8, 9] focused on three cytokines:
interleukin 1 beta (IL-1b), interleukin 6 (IL-6), and tumor
necrosis factor alpha (TNF alpha); two chemokines: chemo-
kine ligand 2 (CCL2) and CXC chemokine ligand 8 (CXCL8);
and the long pentatraxin, pentraxin 3 (PTX3) [10]. The
primary aims were (a) to assess plasma levels of the selected
inﬂammatory molecules in prostate cancer patients under-
going radical radiotherapy; (b) to study inﬂammatory
molecule kinetics as a function of radiation dose and
follow-up time; (c) to investigate the relationship between
plasma levels of the selected inﬂammatory molecules and
acute/late radiation-induced intestinal toxicity; and (d) to
verify if abdominal surgery prior to radiotherapy inﬂu-
ences the absolute plasma levels of inﬂammatory mole-
cules and/or their kinetics.
2. Materials and Methods
2.1. Study Population. Twenty patients with a diagnosis of
histologically conﬁrmed, locally conﬁned, prostate adenocar-
cinoma and receiving deﬁnitive intensity-modulated radia-
tion therapy (IMRT) at 78Gy (2Gy/fraction) were enrolled
in this pilot study. Six patients received neoadjuvant/
adjuvant hormone therapy. Detailed characteristics of the
patient population are given in Table 1. Patients were
recruited from March 2011 to June 2012. This study was
approved by the Fondazione IRCCS Istituto Nazionale dei
Tumori Ethics Committee (INT 67/10), and written
informed consent was obtained from all subjects prior to
study enrolment.
2.2. Patient Blood Sampling, Processing, and Analysis. Ten
millilitres of EDTA blood samples were obtained before
radiotherapy (baseline), after a dose of 8Gy, after 50Gy, at
radiotherapy end and one month after treatment completion.
Samples were centrifuged for 20minutes at 2200 r.c.f./4°C
and immediately stored at ≤−80°C until analysis.
All analyses were carried out blind to patient and therapy
factors. The amount of IL-1b, IL-6, CXCL8, TNF alpha,
CCL2, and PTX3 was determined using commercially
available ELISA kits (R&D Systems Inc., Minneapolis, MN,
USA), according to the manufacturer’s protocols.
2.3. Grading Radiation-Induced Acute Toxicity. Patients were
examined at the start of treatment, once weekly during
treatment, at the end of RT, and every six months thereafter
till 5-year follow-up. Radio-induced was scored using a self-
administered questionnaire. The questionnaire was previ-
ously used and validated in a pilot study with a subset of 50
patients enrolled within the retrospective study AIROPROS
0101 [11]. It consists of 10 questions, the answers to which
are worded to be compatible with a 4-point categorical scale
(1, not at all; 2, a little; 3, much; and 4, very much) which
correspond to the SOMA/LENT (subjective objective man-
agement analytic/late eﬀects on normal tissue) grading. With
this questionnaire, four major types of rectal injury can be
evaluated for rectal bleeding and mucosal loss, sphincter con-
trol and continence, stool frequency, and pain and urgency.
English version of the questionnaire is reported in [12].
Acute rectal symptoms were deﬁned as the maximum
grade reached within one month after radiotherapy end. Late
Table 1: Details on study population characteristics.
Variable^
Age 71 yrs (53–78 yrs)
PSA at diagnosis 7 ng/ml (2.5–14.8)
Clinical stage 13 cT1
5 cT2
2 cT3
Gleason pattern score 13 GPS = 3 + 3
7 GPS = 3 + 4
Neoadjuvant/adjuvant hormone therapy 6
BMI 25 (24–32)
Diabetes 1
Hypertension 13
Previous abdominal surgery 12
Use of anticoagulants 2
^Median value is reported together with range for continuous variable and
prevalence of patients with the selected feature for dichotomic/categorical
variables. PSA: prostate-speciﬁc antigen; BMI: body mass index; yrs: years.
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symptoms were determined as the maximum grade reached
between 6 months and 5 years after treatment completion.
2.4. Statistical Analysis. All analyses were done using
MedCalc (1993–2017 MedCalc Software bvba).
The Mann–Whitney U test was used to compare
baseline/end of treatment plasma levels of the selected
inﬂammatory molecules in patients with/without an abdom-
inal surgery before radiotherapy.
Longitudinal evaluation of inﬂammatory molecule
kinetics during radiotherapy and one month after treatment
completion was analyzed in the frame of one-way analysis
of variance (ANOVA) for multiple measures, in order to
discover patterns of systematic variation with time.
3. Results
3.1. Results on Inﬂammatory Molecule Levels. Detailed
descriptive results on plasma levels of the selected
inﬂammatory molecules for all measurement points are
given in Table 2 and Figure 1. IL-1b and IL-6 were fairly
undetectable in most patients and presented with very low
variability among patients.
TNF alpha levels were signiﬁcantly diﬀerent at baseline
in patients with/without a previous abdominal surgery,
median values 2.1 pg/ml versus 4.8 pg/ml, p = 0 05. CCL2
levels were lower in patients with surgery, both at baseline
and radiotherapy end, but diﬀerences did not reach statis-
tical signiﬁcance (124.0 pg/ml versus 138.2 pg/ml, p = 0 22,
and 150.5 pg/ml versus 168.2 pg/ml, p = 0 10, resp.).
Results of ANOVA for repeated measures are reported in
Table 3. CCL2 was the most interesting marker, showing
signiﬁcant linear increase during and after radiotherapy.
Median values were 127.4 pg/ml (baseline), 134.6 pg/ml
(8Gy), 145.8 pg/ml (50Gy), 154.8 pg/ml (radiotherapy end),
and 143.2 pg/ml (1 month after radiotherapy completion),
p range: 0.01–0.05. PTX3 showed a quadratic trend, with
a maximum at 8Gy (p = 0 01), all other inﬂammatory
Table 2: Detailed descriptive results on plasma levels of the selected inﬂammatory molecules for all measurement points.
pg/ml or ng/ml^ Mean SD Median Minimum Maximum 75th perc 25th perc
CCL2 baseline 131.5 32.1 127.4 66.7 203.3 110.0 139.8
CCL2 8Gy 136.8 37.7 134.6 60.5 200.4 111.9 171.4
CCL2 50Gy 146.6 41.8 145.8 57.7 217.1 118.6 167.1
CCL2 end RT 157.3 34.5 158.4 102.6 240.8 131.2 174.1
CCL2 1mos 167.9 79.7 143.2 74.6 461.7 127.5 187.2
IL-1b baseline 0.0 0.0 0.0 0.0 0.2 0.0 0.0
IL-1b 8Gy 0.0 0.1 0.0 0.0 0.5 0.0 0.0
IL-1b 50Gy 0.0 0.0 0.0 0.0 0.0 0.0 0.0
IL-1b end RT 0.0 0.0 0.0 0.0 0.0 0.0 0.0
IL-1b 1mos 0.0 0.0 0.0 0.0 0.2 0.0 0.0
IL-6 baseline 1.6 1.2 1.6 0.0 3.5 0.3 2.5
IL-6 8Gy 1.4 1.3 2.1 0.0 3.2 0.2 2.3
IL-6 50Gy 1.6 1.4 1.6 0.0 4.7 0.2 2.3
IL-6 end RT 1.6 1.1 1.8 0.0 3.2 1.3 2.3
IL-6 1mos 1.7 1.2 2.2 0.0 3.9 0.5 2.5
CXCL8 baseline 5.7 2.0 5.2 3.7 10.4 4.3 5.9
CXCL8 8Gy 5.5 2.4 4.6 3.4 12.5 3.9 6.4
CXCL8 50Gy 5.7 2.0 5.1 3.7 11.4 4.4 6.2
CXCL8 end RT 6.3 2.7 5.4 2.9 13.4 4.6 7.7
CXCL8 1mos 8.3 9.1 5.7 4.1 46.1 4.7 7.2
PTX3 baseline 3.3 1.1 3.0 1.8 5.6 2.3 4.3
PTX3 8Gy 3.9 1.2 3.9 1.9 6.3 3.1 4.6
PTX3 50Gy 3.3 1.1 3.3 1.6 5.6 2.5 4.0
PTX3 end RT 3.5 1.3 3.7 1.4 6.3 2.6 4.1
PTX3 1mos 3.1 1.1 3.1 1.1 5.1 2.0 4.0
TNF alpha baseline 3.1 2.5 3.9 0.0 7.4 0.4 4.9
TNF alpha 8Gy 2.7 2.3 2.9 0.0 6.5 0.4 4.9
TNF alpha 50Gy 2.8 2.6 2.7 0.0 9.2 0.2 4.6
TNF alpha end RT 2.7 2.2 2.8 0.0 6.1 0.2 4.5
TNF alpha 1mos 3.1 2.2 3.6 0.0 7.0 1.2 4.3
^pg/ml for IL-1b, IL-6, CXCL8, CCL2, and TNF alpha; ng/ml: PTX3; SD: standard deviation; perc: percentile; 1 mos: 1 month; RT: radiotherapy.
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Figure 1: Continued.
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Figure 1: Plasma levels of the selected inﬂammatory molecules for all measurement points: absolute values (a, c, e, g, i, and k) and absolute
variations with respect to baseline (b, d, f, h, j, and l). 1mos: 1 month; RT: radiotherapy. Units of measure are pg/ml for IL-1b, IL-6, CXCL8,
CCL2, and TNF alpha; ng/ml: PTX3.
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markers did not exhibit systematic changes with radiother-
apy dose/time.
CCL2 levels at radiotherapy end could be modelled using
linear regression including the following variables: baseline
CCL2 (coeﬃcient = 1.15, p = 0 0001), age (coeﬃcient =
−3.26, p = 0 004), abdominal surgery (coeﬃcient = 23.3,
p = 0 09), hypertension (coeﬃcient = 29.6, p = 0 02), and use
of anticoagulants (coeﬃcient = 41.0, p = 0 05) and multiple
correlation coeﬃcient = 0.89 (see plot). Signiﬁcance level of
analysis of variance for this linear regression was p = 0 002,
multiple correlation coeﬃcient was 0.87, and coeﬃcient of
determination R2 was 0.75. Figure 2 shows the calibration
plot (observed CCL2 levels at radiotherapy end versus
CCL2 values as predicted by the linear regression model).
3.2. Results on Radio-Induced Toxicity. Three out of twenty
patients (15%) reported grade 2 acute rectal toxicity, while
4/20 (20%) were scored as grade 2 late rectal toxicity in the
ﬁrst 36 months after radiotherapy completion. No grade
3-4 event was observed. Details on incidence of acute
and late grade≥ 1 toxicity (as determined by questions in
the questionnaire) are reported in Table 4.
Multiple toxicity symptoms (>3) were experienced
by 56.3% and 43.8% of patients in the acute and late
phase, respectively.
The 4 patients with late toxicity had CCL2 values at
radiotherapy end above the median value.
Detailed comparison of plasma levels for selected
inﬂammatory markers for patients with/without multiple
symptoms of acute/late intestinal toxicity is reported in
Table 5. t-test was statistically diﬀerent only for baseline
TNF alpha: 2.0 versus 4.7 ng/ml, p = 0 04.
Incidence of acute fecal incontinence and rectal bleeding
was slightly higher in the group of patients with previous
abdominal surgery, 11% versus 0% and 33.3% versus 28.6%
for incontinence and bleeding, respectively, diﬀerences were
not statistically signiﬁcant. Late rectal bleeding was also
slightly higher for patients with previous abdominal surgery,
33.3% versus 28.6%, diﬀerence was not statistically signiﬁ-
cant. 67% of patients with abdominal surgery presented with
at least three diﬀerent acute intestinal toxicity symptoms
versus 43% in the rest of the population; even in this case,
diﬀerence was not statistically signiﬁcant due to the very
small size of the population of this pilot study.
4. Discussion
Preclinical and clinical studies have shown that radiotherapy
induces cytokine responses that could play a major role in
mediating radiation toxicity [3–6].
In the present study, grade≥ 1 acute and late intestinal
toxicity (as deﬁned by questions in the patient-reported
questionnaire) were not found to be signiﬁcantly associated
with plasma levels of inﬂammatory markers, with the only
exception of baseline TNF alpha level, which was higher in
patients experiencing multiple late intestinal toxicity symp-
toms. The small size of the study population could highlight
only important diﬀerences, larger populations are required to
investigate more modest variations.
When considering inﬂammatory molecule kinetics
during and immediately after radiotherapy, CCL2 was found
to signiﬁcantly increase during IMRT. Though statistical
association between moderate/severe radio-induced (acute
and late) intestinal toxicity and CCL2 levels could not be
investigated due to the low size of the study population,
patients exhibiting late grade 2 toxicity were found to have
Table 3: Results of one-way analysis of variance for repeated
measures for all considered markers. Best trend for marker values
as a function of time is reported.
Best trend p value
IL-1b Cubic 0.34
IL-6 Quadratic 0.16
CXCL8 Linear 0.19
CCL2 Linear 0.01∗
TNF alpha Quadratic 0.07
PTX3 Quadratic 0.06
∗Statistically signiﬁcant.
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Figure 2: Calibration plot for the linear regression model predicting
CCL2 levels at end of radiotherapy (observed CCL2 levels at
radiotherapy end versus CCL2 values as predicted by the linear
regression). Details are given in the text. Units of measure pg/ml.
RT: radiotherapy.
Table 4: Details on incidence of acute and late grade≥ 1 toxicity
(as determined by questions in the questionnaire).
Acute incidence
grade≥ 1
Late incidence
grade≥ 1
Stool frequency 50.0% 50.0%
Diarrhea 62.5% 31.3%
Tenesmus 43.8% 25.0%
Stool urgency 31.3% 43.8%
Fecal incontinence 6.3% 6.3%
Rectal pain 18.8% 25.0%
Rectal bleeding 31.3% 31.3%
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CCL2 levels at the end of radiotherapy above the median
value for the study cohort.
Interestingly, CCL2 levels at the end of radiotherapy
could be modelled through linear regression including age,
abdominal surgery, hypertension, and use of anticoagulants.
All these features are known to be risk factors for
increase intestinal toxicity after prostate cancer radiother-
apy [13–15], thus suggesting a ﬁrst possible link between
patient clinical characteristics and his individual response
in terms of biomarkers.
CCL2 is a low molecular weight monomeric polypeptide
whose primary function was identiﬁed as promoting mono-
cyte and macrophage migration to sites of inﬂammation
[16]. For example, CCL2 is involved in monocyte inﬁltration
in inﬂammatory diseases such as rheumatoid arthritis as well
as in the inﬂammatory response against tumours.
There are limited data regarding the relationship between
CCL2 and radiation exposure. Most results are related to the
evidence that CCL2 overexpression in tumour is associated
with macrophage inﬁltration and poor prognosis in human
cancers and may play a pivotal role in creating the fertile
environment in the bone for metastasis [17–19].
Connolly and coworkers [20] demonstrated that radio-
therapy stimulates increased production CCL2 and CCL5 at
the tumour site, while Kalbasi and colleagues [21] found that
ablative radiotherapy for pancreatic ductal adenocarcinoma
led to a signiﬁcant increase in CCL2 production by tumour
cells, with genetic deletion of CCL2 in pancreatic ductal
adenocarcinoma cells improving radiotherapy eﬃcacy.
When considering the association between CCL2 expres-
sion and response of normal tissues to radiation, only two
studies are available in the literature and they reported inter-
esting results. Lee et al. [22] showed that irradiation induces a
transient nonclassical cytokine response with selective upreg-
ulation of CCL2. Interestingly, absence of CCL2 signalling in
the hours after irradiation is suﬃcient to restore hippocam-
pal neurogenesis and to decrease the risk of long-term defects
in neural stem cell function following cranial radiation in
children. Holler and coworkers [23] demonstrated that prav-
astatin has a mitigatory eﬀect on radiation-induced vascular
dysfunction in the skin in a mouse model. Remarkably, prav-
astatin limits the radio-induced increase of blood CCL2
expression and inﬂammatory cell migration in tissues.
When considering the other measured inﬂammatory
molecules, IL-1b and IL-6 were fairly undetectable in most
patients and presented with very low variability among
patients: for these reasons, they were considered of no inter-
est for the purpose of the present study. TNF alpha levels
were found to be signiﬁcantly diﬀerent between patients
with/without a previous abdominal surgery, but it did not
Table 5: Comparison of plasma levels for the selected inﬂammatory molecules in subgroups of patients experiencing multiple symptoms (≥3)
for intestinal acute/late toxicity. p values for test are reported.
Acute toxicity Late toxicity
Patients with
<3 symptoms
Patients with
≥3 symptoms t-test
Patients with
<3 symptoms
Patients with
≥3 symptoms t-test
Mean SD Mean SD Mean diﬀ p Mean SD Mean SD Mean diﬀ p
CCL2 baseline 139.4 34.1 134.2 30.4 −5.2 0.75 145.5 37.3 124.9 16.5 −20.7 0.18
CCL2
50Gy
155.7 33.9 159.7 40.9 4.1 0.83 162.4 38.5 152.3 36.7 −10.1 0.60
CCL2
end RT
161.2 20.7 165.8 42.4 4.6 0.79 165.5 39.1 161.6 28.1 −3.9 0.82
CCL2 1mos 153.2 40.0 201.3 104.2 48.1 0.25 193.9 107.4 162.6 39.6 −31.3 0.46
IL-8 baseline 6.9 2.7 5.2 1.5 −1.7 0.15 6.4 2.6 5.4 1.6 −0.9 0.40
IL-8
50Gy
6.6 2.5 5.4 1.9 −1.2 0.29 6.2 2.4 5.6 2.0 −0.6 0.60
IL-8
end RT
8.2 3.2 5.4 2.1 −2.8 0.06 7.6 3.1 5.4 2.3 −2.2 0.13
IL-8
1mos
7.1 2.2 10.6 13.4 3.4 0.50 11.6 13.0 5.8 2.1 −5.8 0.25
PTX3 baseline 3.1 1.2 3.2 1.1 0.2 0.75 2.9 1.1 3.5 1.0 0.5 0.37
PTX3
50Gy
3.3 1.5 3.1 1.1 −0.2 0.72 3.3 1.4 3.0 1.1 −0.3 0.69
PTX3
end RT
3.2 1.4 3.4 1.4 0.2 0.80 3.6 1.7 3.0 0.8 −0.6 0.40
PTX3 1mos 3.2 1.3 3.0 1.2 −0.2 0.72 3.1 1.2 3.1 1.3 0.0 0.98
TNF alpha baseline 2.0 2.3 4.0 2.6 2.0 0.13 2.0 2.2 4.7 2.3 2.7 0.04
TNF alpha 50Gy 2.1 2.5 3.6 3.0 1.5 0.29 2.0 2.4 4.0 3.1 2.0 0.17
TNF alpha end RT 1.9 2.3 3.3 2.4 1.3 0.27 1.9 2.2 3.7 2.3 1.8 0.14
TNF alpha 1mos 2.3 2.3 3.8 2.3 1.5 0.23 2.5 2.6 4.1 1.8 1.6 0.17
^pg/ml for IL-1b, IL-6, CXCL8, CCL2, and TNF alpha; ng/ml: PTX3; SD: standard deviation; 1 mos: 1 month; RT: radiotherapy; diﬀ: diﬀerence.
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exhibit signiﬁcant changes as a function of radiation dose and
did not result to be associated to acute/late toxicity. PTX3
showed a quadratic trend with an early increase with dose
(at 8Gy) with subsequent return to baseline levels by the
end of treatment. Increase in PTX3 was not associated with
patient-reported morbidity.
To our knowledge, there is only one previously published
study investigating cytokine expression during IMRT for
prostate cancer and their relationship with acute toxicity
[24]. Their study population consisted of 22 prostate patients
treated with exclusive IMRT (78Gy at 2Gy/fraction) and 20
patients receiving radiotherapy after prostatectomy (70Gy at
2Gy/fraction). They found IL-6 levels to be signiﬁcantly ele-
vated over baseline in the postprostatectomy group but no
signiﬁcant diﬀerence in the exclusive IMRT cohort. Increases
in IL-2 and IL-1 levels over baseline were signiﬁcantly associ-
ated with increased gastrointestinal and genitourinary toxic-
ity, respectively, regardless of the radiotherapy regimen
(exclusive IMRT versus postprostatectomy IMRT) regimen,
while the analysis of IL-6 suggested that the increase of IL-6
was associated with a higher risk for gastrointestinal toxicity
but it did not reach statistical signiﬁcance.
Presence of previous abdominal surgery was not found to
be signiﬁcantly associated with toxicity or to plasma levels of
inﬂammation markers in this pilot study. As already pointed
out, interestingly, previous abdominal surgery was included
as a factor modulating CCL2 levels at radiotherapy end,
together with other patient features known to be predictors
of intestinal toxicity. This modulating eﬀect should be con-
ﬁrmed on a wider population, in order to suggest a direct
eﬀect of factors associated with toxicity on CCL2 levels at
radiotherapy end.
Besides interest in the comprehension of the biological
rationale for the correlation of some clinical factors with
morbidity, investigation of association between inﬂamma-
tory molecule levels and radio-induced toxicity is of interest
because it could have the potential of being a biological
measure of the individual patient radiosensitivity, thus
prompting further optimization of radiotherapy treatment
for more sensible patients or dose escalation on resistant
patients. Prophylactic treatment of toxicity symptoms could
also be proposed in patients at higher risk of enhanced
inﬂammation processes.
One important limitation of this study is related to the
limited sample size. Our pilot study was intended to be
exploratory, to inspect the feasibility of multiple blood
samples for biomarker investigation in the frame of clinical
practice and to validate the study methodology. These results
are expected to guide future, larger trials which could estab-
lish the time course of plasma levels of inﬂammatory mole-
cules after radiotherapy and how they are associated with
normal tissue radiation toxicity. Speciﬁc future research
topics should include evaluation of a wider spectrum of
radio-induced symptoms (e.g., including urinary and hema-
tologic toxicities) and of populations of patients treated with
radiotherapy for diﬀerent cancer types, such as head-and-
neck patients or breast cancer patients. Interaction with
concomitant oncological treatment (such as chemotherapy
or hormone therapy) should be considered.
5. Conclusions
This preliminary study identiﬁed a correlation between CCL2
levels at the end of radiotherapy and basal CCL2, age, and
surgery, suggesting a diﬀerent response to radiotherapy in
older patients and in patients with pretreatment abdominal
surgery. Interestingly, these clinical characteristics are the
same features included in predictive models for acute and late
rectal toxicity. Larger accrual is needed to conﬁrm these feasi-
bility results and to study the association with radio-induced
acute and late toxicity.
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